Investigational drug · Phase 3
AD-218
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mixed Dyslipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AD-218"
First trial start
2022
Jul 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-218", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mixed Dyslipidemia
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-218" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of AD-218Pivotal-lookingRecruiting
Addpharma Inc.Industry
NCT05400317 · 520 participants (planned) · Start Jul 27, 2022 · Primary completion Mar 31, 2026
Drug: AD-218; AD-218A · For: Mixed Dyslipidemia
Sites: Daegu, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Mixed Dyslipidemia
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- AD-218APhase 31 trial
Addpharma Inc. · Mixed Dyslipidemia
- DW5421APhase 31 trial
Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia
- DW5421BPhase 31 trial
Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia
- EDP167Phase 22 trials
Eddingpharm (Zhuhai) Co., Ltd. · Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia (HoFH)
- BW-00112Phase 21 trial
Shanghai Argo Biopharmaceutical Co., Ltd. · Mixed Dyslipidemia
- MWX203Phase 21 trial
Shanghai Minwei Biotechnology Co., Ltd · Mixed Dyslipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.